The landscape of game modding has shifted dramatically in 2026, with AI tools moving beyond simple code snippets to become full-fledged development partners. Microsoft Copilot has integrated deeply ...

Multiple dapagliflozin generic approvals are expected to intensify near-term market competition, requiring manufacturers to coordinate production readiness, launch timing, and labeling compliance ...

Generic dapagliflozin is indicated to lower heart failure hospitalization risk in type 2 diabetes with established cardiovascular disease or multiple risk factors, and to improve glycemic control ...

Patients in Canada have been paying between $300 and $400 a month for Ozempic and Wegovy, depending on the prescribed dose You can save this article by registering for free here. Or sign-in if you ...

The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...

The plaintiff alleged a vast, industry-wide conspiracy in North America in which the defendants conspired to allocate the generic drug market and fix prices at the maximum public formulary price in ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...

When you’re standing at the pharmacy counter, it’s easy to assume the brand-name medication your doctor prescribed is the only option available. But in reality, many pharmacy shelves that stock ...

The settlement agreement will extend market exclusivity for AbbVie’s JAK inhibitor in the U.S. until 2037—providing pediatric exclusivity is granted. AbbVie has reached a settlement with generic ...

With Rinvoq and its sibling medicine Skyrizi having successfully picked up the sales torch in the wake of Humira’s tumble over the patent cliff, AbbVie is working to cover its legal bases so the ...